Towa International exceeds 330 million euros in revenue and closes the 2024 fiscal year with 5% growth

• Towa International expands its international presence with agreements in 10 new countries.
• Breckenridge Pharmaceutical, Towa International’s U.S. company, strengthens the group’s presence in the U.S. with its entry into the institutional channel.
• The company increases its investment in the Barcelona production plant with the construction of a new high-containment area.

Barcelona, July 8, 2025. Towa International, an international pharmaceutical holding company specializing in the research, development, manufacturing, and distribution of generic medicines, which markets directly in Europe and the United States through its companies, Towa Pharmaceutical Spain, Italy, and Portugal, and Breckenridge Pharmaceutical, and in more than 42 countries through its company Towa2B, closed the year 2024 with revenue exceeding 330 million euros, representing a 5% growth compared to the previous year.

Since its beginnings in 2020, Towa International has established itself as the international hub of Towa Pharmaceutical Co., Ltd., a Japanese parent company that this year achieved a historic record of 1.6 billion euros in net sales. This milestone reaffirms the group’s strength as a leader in the generics market in Japan and as the only company in the sector with a presence outside the country, with Towa International leading all international markets.

David Peix, CEO of Towa International, states: “In 2024 we strengthened our roadmap with our 2024–2026 Strategic Plan, which marks the beginning of a new stage for the company, structured around three major pillars: delivering more value, expanding our international presence, and increasing our investment in development. All of this is always hand in hand with the people who are part of Towa International and guided by our Ikigai, our purpose: to contribute to people’s health and bring genuine smiles.”

During 2024, Breckenridge Pharmaceutical, Towa International’s U.S. company, consolidated its entry into the institutional channel and expanded its presence in the U.S. healthcare system with the launch of two new medicines: Everolimus tablets for oral suspension (TFOS) and Methadone hydrochloride multi-dose injectable. These developments reinforce the group’s global commitment to improving equitable and affordable access to medicines for patients, and to offering more therapeutic solutions to meet their needs.

In Europe, Towa International has continued to strengthen its presence through its companies Towa Pharmaceutical Spain, Italy, and Portugal, expanding its generic medicines portfolio and diversifying its offering in the pharmacy channel with the launch of new OTC products.

International expansion has been another of the year’s main levers. With a commitment to reaching more people around the world, Towa International has formalized strategic agreements in 10 new countries outside Europe, further strengthening its global presence through its company Towa2B, which currently operates in more than 42 countries. With a focus on patients and their diverse realities, Towa International has made it a priority in the coming years to reach people in Latin America, North Africa, and the Middle East, to respond to the healthcare needs of diverse populations and contribute to more equitable access to medicines.

Towa International’s focus on value has also translated into industrial investment. The company has begun construction of a new high-containment area (HPAPI) at its Martorelles (Barcelona) plant, a facility dedicated to highly potent medicines with a focus on oncology and immunosuppression. With an investment of over 10 million euros, the new area will be operational in the third quarter of 2026 and will allow for the production of batches ranging from 10 to 150 kg. With this expansion, the plant will reach a production capacity of over 6 billion doses annually.

Carlos Prieto, CFO of Towa International, adds: “In an increasingly demanding environment for the pharmaceutical industry, marked by greater regulatory pressure, rising costs, and a volatile global context, we have, after our first five years, consolidated results that reflect a solid, prudent, and at the same time ambitious financial management. We have managed to combine operational profitability with strong reinvestment capacity and are prepared to face the next milestones of our strategic plan.”

In 2024, Towa International formalized its new CMO/CDMO business unit at its Martorelles plant, with the aim of offering its knowledge, experience, and development and production capabilities to other pharmaceutical companies, both generic and innovative. At the same time, the company diversifies its value proposition within the pharmaceutical ecosystem.

In parallel, the company continues to make progress in sustainability. In 2024, Towa International completed its gap analysis in accordance with the initial requirements of the European regulatory framework and the CSRD Directive. Beyond regulatory changes, the company maintains its ESG roadmap as a strategic commitment aligned with its long-term commitment to environmental, social, and governance responsibility.